Surmodics (SRDX) Financials

$28.70 -0.46 (-1.58%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$28.74 +0.04 (+0.12%)

As of 05/23/2025 04:04 PM Eastern

Annual Income Statements for Surmodics

This table shows Surmodics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021
Period end date	9/30/2024	9/30/2023	9/30/2022	9/30/2021
Net Income / (Loss) Attributable to Common Shareholders	-12	-1.54	-27	4.24
Consolidated Net Income / (Loss)	-12	-1.54	-27	4.24
Net Income / (Loss) Continuing Operations	-12	-1.54	-27	4.24
Total Pre-Tax Income	-7.51	2.49	-22	6.35
Total Operating Income	-5.65	5.15	-22	6.70
Total Gross Profit	93	108	80	88
Total Revenue	126	133	100	105
Operating Revenue	126	133	100	105
Total Cost of Revenue	33	25	20	17
Operating Cost of Revenue	33	25	20	17
Total Operating Expenses	99	102	102	81
Selling, General & Admin Expense	57	52	47	31
Research & Development Expense	38	47	51	47
Amortization Expense	3.50	3.54	4.15	2.79
Other Operating Expenses / (Income)	0.00	-0.83	0.01	0.00
Restructuring Charge	0.00	1.28	0.00	1.05
Total Other Income / (Expense), net	-1.86	-2.66	-0.40	-0.36
Interest Expense	3.54	3.49	0.60	0.31
Interest & Investment Income	1.92	1.08	0.10	0.12
Other Income / (Expense), net	-0.24	-0.25	0.10	-0.17
Income Tax Expense	4.04	4.02	4.78	2.11
Basic Earnings per Share	($0.82)	($0.11)	($1.96)	$0.31
Weighted Average Basic Shares Outstanding	14.15M	14.03M	13.92M	13.77M
Diluted Earnings per Share	($0.82)	($0.11)	($1.96)	$0.30
Weighted Average Diluted Shares Outstanding	14.15M	14.03M	13.92M	13.99M
Weighted Average Basic & Diluted Shares Outstanding	14.33M	14.16M	14.04M	13.91M

This table shows Surmodics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022	6/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-5.21	-3.65	-7.55	0.25	-0.79	6.69	7.35	-7.73	-7.84	-15	-5.65
Consolidated Net Income / (Loss)	-5.21	-3.65	-7.55	0.25	-0.79	6.69	7.35	-7.73	-7.84	-15	-5.65
Net Income / (Loss) Continuing Operations	-5.21	-3.65	-7.55	0.25	-0.79	6.69	7.35	-7.73	-7.84	-15	-5.65
Total Pre-Tax Income	-4.68	-2.94	-5.81	0.17	-0.72	-2.79	21	-7.37	-8.01	-6.79	-7.18
Total Operating Income	-4.01	-2.48	-5.37	0.66	-0.32	-2.45	21	-6.58	-7.23	-6.61	-7.14
Total Gross Profit	20	22	22	25	22	21	46	21	20	20	20
Total Revenue	28	30	30	32	31	28	52	27	25	26	25
Operating Revenue	28	30	30	32	31	28	52	27	25	26	25
Total Cost of Revenue	7.83	7.43	8.45	7.10	8.80	7.04	6.92	5.74	5.27	5.60	5.14
Operating Cost of Revenue	7.83	7.43	8.45	7.10	8.80	7.04	6.92	5.74	5.27	5.60	5.14
Total Operating Expenses	24	25	27	24	22	23	24	28	27	27	27
Selling, General & Admin Expense	15	15	17	13	13	13	13	13	13	14	13
Research & Development Expense	8.37	8.94	9.77	10	8.66	9.70	11	13	13	12	13
Amortization Expense	0.85	0.86	0.87	0.88	0.87	0.88	0.88	0.87	0.91	0.97	1.02
Total Other Income / (Expense), net	-0.67	-0.46	-0.44	-0.49	-0.40	-0.34	-0.76	-0.78	-0.78	-0.18	-0.04
Interest Expense	0.86	0.88	0.88	0.88	0.90	0.90	0.88	0.88	0.83	0.19	0.15
Interest & Investment Income	0.25	0.39	0.49	0.46	0.54	0.55	0.18	0.18	0.17	0.03	0.02
Other Income / (Expense), net	-0.07	0.03	-0.05	-0.07	-0.05	0.01	-0.06	-0.08	-0.13	-0.02	0.09
Income Tax Expense	0.53	0.71	1.74	-0.08	0.06	-9.48	13	0.37	-0.17	7.94	-1.53
Basic Earnings per Share	($0.36)	($0.26)	($0.53)	$0.02	($0.06)	$0.48	$0.52	($0.55)	($0.56)	($1.06)	($0.41)
Weighted Average Basic Shares Outstanding	14.28M	14.23M	14.17M	14.15M	14.10M	14.03M	14.05M	14.03M	13.98M	13.92M	13.93M
Diluted Earnings per Share	($0.36)	($0.26)	($0.53)	$0.02	($0.06)	$0.48	$0.52	($0.55)	($0.56)	($1.06)	($0.41)
Weighted Average Diluted Shares Outstanding	14.28M	14.23M	14.17M	14.18M	14.10M	14.03M	14.07M	14.03M	13.98M	13.92M	13.93M
Weighted Average Basic & Diluted Shares Outstanding	14.30M	14.30M	14.27M	14.26M	-	14.16M	14.13M	14.13M	14.13M	14.04M	14.01M

This table details how cash moves in and out of Surmodics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021
Period end date	9/30/2024	9/30/2023	9/30/2022	9/30/2021
Net Change in Cash & Equivalents	-5.30	22	-12	0.37
Net Cash From Operating Activities	0.25	11	-17	15
Net Cash From Continuing Operating Activities	0.25	11	-17	15
Net Income / (Loss) Continuing Operations	-12	-1.54	-27	4.24
Consolidated Net Income / (Loss)	-12	-1.54	-27	4.24
Depreciation Expense	8.69	8.52	9.14	8.02
Amortization Expense	0.30	0.37	0.05	0.05
Non-Cash Adjustments To Reconcile Net Income	3.24	7.43	6.34	3.81
Changes in Operating Assets and Liabilities, net	-0.44	-4.27	-5.47	-0.72
Net Cash From Investing Activities	-2.94	-6.82	6.23	-25
Net Cash From Continuing Investing Activities	-2.94	-6.82	6.23	-25
Purchase of Property, Plant & Equipment	-3.49	-2.92	-3.37	-5.28
Acquisitions	0.00	0.00	0.00	-41
Purchase of Investments	-25	-3.90	0.00	-23
Sale and/or Maturity of Investments	26	0.00	9.60	43
Net Cash From Financing Activities	-2.95	18	-0.38	10
Net Cash From Continuing Financing Activities	-2.95	18	-0.38	10
Repayment of Debt	0.00	-11	0.00	0.00
Issuance of Debt	0.00	30	0.00	10
Issuance of Common Equity	1.22	1.25	1.25	3.13
Other Financing Activities, net	-4.17	-1.90	-1.62	-2.90
Effect of Exchange Rate Changes	0.34	0.32	-0.79	-
Cash Interest Paid	3.05	2.92	0.42	0.07
Cash Income Taxes Paid	2.57	2.85	0.42	0.16

This table details how cash moves in and out of Surmodics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022	6/30/2022
Net Change in Cash & Equivalents	-0.96	-5.97	12	-8.73	-18	-3.16	25	-7.25	7.43	-1.08	-4.64
Net Cash From Operating Activities	0.95	-7.89	3.66	-2.03	-8.79	1.25	26	-5.83	-11	-2.50	-3.50
Net Cash From Continuing Operating Activities	0.95	-7.89	3.66	-2.03	-8.79	1.25	26	-5.83	-11	-2.50	-3.50
Net Income / (Loss) Continuing Operations	-5.21	-3.65	-3.45	-7.55	-0.79	6.69	7.35	-7.73	-7.84	-15	-5.65
Consolidated Net Income / (Loss)	-5.21	-3.65	-3.45	-7.55	-0.79	6.69	7.35	-7.73	-7.84	-15	-5.65
Depreciation Expense	2.14	2.08	2.14	2.13	2.33	2.16	2.15	2.09	2.12	2.24	2.21
Amortization Expense	0.08	0.08	0.08	0.08	0.08	0.09	0.09	0.10	0.08	0.01	0.01
Non-Cash Adjustments To Reconcile Net Income	3.12	2.47	2.46	0.86	-1.40	2.82	2.66	-0.86	2.81	1.39	3.25
Changes in Operating Assets and Liabilities, net	0.82	-8.87	2.43	2.45	-9.02	-11	14	0.57	-7.97	8.58	-3.31
Net Cash From Investing Activities	-2.28	3.70	9.46	-6.72	-8.47	-4.65	-0.47	-0.72	-0.98	1.43	-0.86
Net Cash From Continuing Investing Activities	-2.28	3.70	9.46	-6.72	-8.47	-4.65	-0.47	-0.72	-0.98	1.43	-0.86
Purchase of Property, Plant & Equipment	-0.32	-0.30	-0.54	-0.96	-0.72	-0.75	-0.47	-0.72	-0.98	-0.57	-0.86
Purchase of Investments	-1.96	0.00	-	-12	-9.75	-3.90	-	-	-	-	-
Net Cash From Financing Activities	0.05	-1.20	-1.56	0.07	-1.05	0.42	-0.02	-0.79	19	0.30	-0.01
Net Cash From Continuing Financing Activities	0.05	-1.20	-1.56	0.07	-1.05	0.42	-0.02	-0.79	19	0.30	-0.01
Issuance of Common Equity	0.06	0.11	0.55	0.09	0.04	0.45	-	0.46	0.35	0.48	0.02
Other Financing Activities, net	-0.02	-1.31	-2.12	-0.03	-1.09	-0.03	-0.02	-0.99	-0.86	-0.19	-0.04
Effect of Exchange Rate Changes	0.32	-0.57	-	-	0.25	-	-	0.09	0.41	-0.30	-0.27
Cash Interest Paid	0.69	0.79	0.76	0.77	0.78	0.76	0.76	0.73	0.66	0.16	0.09
Cash Income Taxes Paid	2.33	0.00	0.89	1.34	0.00	2.60	0.24	0.01	0.01	0.02	0.00

This table presents Surmodics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021
Period end date	9/30/2024	9/30/2023	9/30/2022	9/30/2021
Total Assets	179	186	158	195
Total Current Assets	81	87	58	70
Cash & Equivalents	36	41	19	31
Short-Term Investments	4.00	3.93	0.00	7.72
Accounts Receivable	13	11	10	9.17
Inventories, net	15	15	12	6.76
Prepaid Expenses	2.86	7.36	6.76	6.45
Other Current Assets	9.87	7.80	7.12	7.09
Plant, Property, & Equipment, net	25	26	27	30
Total Noncurrent Assets	72	73	74	94
Goodwill	45	43	41	46
Intangible Assets	24	26	28	37
Other Noncurrent Operating Assets	4.09	3.86	4.77	3.72
Total Liabilities & Shareholders' Equity	179	186	158	195
Total Liabilities	60	66	50	55
Total Current Liabilities	21	24	32	30
Short-Term Debt	0.00	-	10	10
Accounts Payable	2.79	2.99	3.14	1.78
Accrued Expenses	3.80	6.44	5.85	4.91
Current Deferred Revenue	1.62	4.38	4.16	4.65
Current Deferred & Payable Income Tax Liabilities	1.24	0.00	-	-
Current Employee Benefit Liabilities	11	10	8.93	8.48
Total Noncurrent Liabilities	39	42	18	25
Long-Term Debt	30	29	0.00	-
Noncurrent Deferred & Payable Income Tax Liabilities	1.79	2.00	2.03	2.74
Other Noncurrent Operating Liabilities	7.78	8.06	11	12
Commitments & Contingencies	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	119	120	108	140
Total Preferred & Common Equity	119	120	108	140
Preferred Stock	0.00	0.00	0.00	0.00
Total Common Equity	119	120	108	140
Common Stock	45	37	29	22
Retained Earnings	76	87	89	116
Accumulated Other Comprehensive Income / (Loss)	-2.13	-4.76	-9.87	1.73

This table presents Surmodics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	12/31/2024	6/30/2024	3/31/2024	6/30/2023	3/31/2023	12/31/2022	6/30/2022
Total Assets	163	164	177	183	189	166	170	176
Total Current Assets	72	72	80	84	86	61	64	60
Cash & Equivalents	29	30	24	33	45	19	26	20
Short-Term Investments	1.97	0.00	14	7.91	-	-	-	2.01
Accounts Receivable	12	13	13	12	12	12	10	9.38
Inventories, net	16	15	15	15	15	14	13	11
Prepaid Expenses	3.25	4.01	3.37	4.20	7.23	8.31	8.07	7.65
Other Current Assets	9.70	9.88	10	11	7.68	7.87	7.05	7.58
Plant, Property, & Equipment, net	23	24	25	26	27	28	28	28
Total Noncurrent Assets	68	68	72	73	76	77	78	87
Goodwill	44	42	43	44	44	44	43	43
Intangible Assets	21	21	24	25	28	29	29	31
Other Noncurrent Operating Assets	3.44	4.41	4.68	4.46	4.84	4.76	5.01	5.51
Total Liabilities & Shareholders' Equity	163	164	177	183	189	166	170	176
Total Liabilities	53	52	59	59	76	64	62	51
Total Current Liabilities	14	13	20	19	32	19	17	29
Accounts Payable	3.39	2.56	3.19	3.19	2.48	3.79	2.04	1.93
Accrued Expenses	3.97	3.58	5.43	5.02	5.45	6.46	7.05	5.86
Current Deferred Revenue	0.34	0.27	3.68	4.75	4.33	3.35	3.77	4.01
Current Deferred & Payable Income Tax Liabilities	0.00	1.89	0.04	0.00	12	-	-	-
Current Employee Benefit Liabilities	6.26	4.88	7.86	6.25	7.83	5.53	4.41	7.60
Total Noncurrent Liabilities	39	39	39	40	44	44	45	21
Long-Term Debt	30	30	30	29	29	29	29	-
Noncurrent Deferred & Payable Income Tax Liabilities	1.61	1.60	1.77	1.86	2.06	2.03	2.10	2.23
Other Noncurrent Operating Liabilities	7.78	7.60	7.79	8.32	9.54	9.74	9.52	12
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	110	112	118	124	112	103	107	125
Total Preferred & Common Equity	110	112	118	124	112	103	107	125
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	110	112	118	124	112	103	107	125
Common Stock	47	46	43	41	35	33	31	27
Retained Earnings	67	72	79	87	81	73	81	104
Accumulated Other Comprehensive Income / (Loss)	-3.87	-6.14	-4.11	-3.75	-3.20	-3.81	-4.62	-5.72

This table displays calculated financial ratios and metrics derived from Surmodics' official financial filings.

Metric	2024	2023	2022
Period end date	9/30/2024	9/30/2023	9/30/2022
Growth Metrics	-	-	-
Revenue Growth	-4.91%	32.65%	-4.93%
EBITDA Growth	-77.45%	207.65%	-187.74%
EBIT Growth	-220.19%	122.27%	-436.66%
NOPAT Growth	-24.23%	79.44%	-445.62%
Net Income Growth	-651.43%	94.37%	-743.71%
EPS Growth	-645.45%	94.39%	-753.33%
Operating Cash Flow Growth	-97.64%	161.05%	-211.92%
Free Cash Flow Firm Growth	-7.46%	-37.19%	83.76%
Invested Capital Growth	4.21%	4.60%	-8.99%
Revenue Q/Q Growth	0.00%	1.52%	2.06%
EBITDA Q/Q Growth	0.00%	43.60%	-92.40%
EBIT Q/Q Growth	0.00%	590.97%	-39.01%
NOPAT Q/Q Growth	0.00%	-560.37%	-38.34%
Net Income Q/Q Growth	0.00%	93.31%	-112.50%
EPS Q/Q Growth	0.00%	93.33%	-113.04%
Operating Cash Flow Q/Q Growth	111.48%	55.44%	-24.50%
Free Cash Flow Firm Q/Q Growth	0.00%	-146.88%	89.79%
Invested Capital Q/Q Growth	0.00%	6.97%	-12.06%
Profitability Metrics	-	-	-
Gross Margin	73.81%	81.17%	79.65%
EBITDA Margin	2.47%	10.40%	-12.81%
Operating Margin	-4.48%	3.88%	-22.11%
EBIT Margin	-4.67%	3.70%	-22.00%
Profit (Net Income) Margin	-9.15%	-1.16%	-27.29%
Tax Burden Percent	153.77%	-61.76%	121.26%
Interest Burden Percent	127.48%	50.77%	102.27%
Effective Tax Rate	0.00%	161.76%	0.00%
Return on Invested Capital (ROIC)	-3.72%	-3.13%	-14.83%
ROIC Less NNEP Spread (ROIC-NNEP)	53.55%	-16.31%	44.39%
Return on Net Nonoperating Assets (RNNOA)	-5.94%	1.78%	-7.12%
Return on Equity (ROE)	-9.67%	-1.35%	-21.95%
Cash Return on Invested Capital (CROIC)	-7.85%	-7.62%	-5.42%
Operating Return on Assets (OROA)	-3.23%	2.85%	-12.46%
Return on Assets (ROA)	-6.34%	-0.89%	-15.45%
Return on Common Equity (ROCE)	-9.67%	-1.35%	-21.95%
Return on Equity Simple (ROE_SIMPLE)	-9.71%	-1.28%	-25.16%
Net Operating Profit after Tax (NOPAT)	-3.95	-3.18	-15
NOPAT Margin	-3.13%	-2.40%	-15.48%
Net Nonoperating Expense Percent (NNEP)	-57.28%	13.19%	-59.22%
Cost of Revenue to Revenue	26.19%	18.83%	20.35%
SG&A Expenses to Revenue	45.08%	39.13%	46.96%
R&D to Revenue	30.43%	35.14%	50.63%
Operating Expenses to Revenue	78.28%	77.29%	101.76%
Earnings before Interest and Taxes (EBIT)	-5.89	4.90	-22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3.11	14	-13
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.65	3.78	3.93
Price to Tangible Book Value (P/TBV)	10.92	8.94	10.77
Price to Revenue (P/Rev)	4.39	3.42	4.26
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	5.01	4.21	4.19
Enterprise Value to Revenue (EV/Rev)	4.30	3.30	4.17
Enterprise Value to EBITDA (EV/EBITDA)	174.56	31.74	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	89.33	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	2,188.37	41.62	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.25	0.25	0.09
Long-Term Debt to Equity	0.25	0.25	0.00
Financial Leverage	-0.11	-0.11	-0.16
Leverage Ratio	1.53	1.51	1.42
Compound Leverage Factor	1.94	0.77	1.45
Debt to Total Capital	19.91%	19.69%	8.45%
Short-Term Debt to Total Capital	0.00%	0.00%	8.45%
Long-Term Debt to Total Capital	19.91%	19.69%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	80.09%	80.31%	91.55%
Debt to EBITDA	9.51	2.13	-0.78
Net Debt to EBITDA	-3.40	-1.16	0.70
Long-Term Debt to EBITDA	9.51	2.13	0.00
Debt to NOPAT	-7.48	-9.24	-0.65
Net Debt to NOPAT	2.67	5.01	0.58
Long-Term Debt to NOPAT	-7.48	-9.24	0.00
Altman Z-Score	7.16	6.00	6.26
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.96	3.62	1.80
Quick Ratio	2.60	2.35	0.92
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-8.33	-7.75	-5.65
Operating Cash Flow to CapEx	7.10%	360.32%	-511.07%
Free Cash Flow to Firm to Interest Expense	-2.35	-2.22	-9.45
Operating Cash Flow to Interest Expense	0.07	3.01	-28.80
Operating Cash Flow Less CapEx to Interest Expense	-0.92	2.18	-34.44
Efficiency Ratios	-	-	-
Asset Turnover	0.69	0.77	0.57
Accounts Receivable Turnover	10.44	12.45	10.19
Inventory Turnover	2.20	1.87	2.19
Fixed Asset Turnover	4.95	4.99	3.49
Accounts Payable Turnover	11.43	8.15	8.27
Days Sales Outstanding (DSO)	34.95	29.32	35.83
Days Inventory Outstanding (DIO)	165.82	194.88	166.68
Days Payable Outstanding (DPO)	31.93	44.80	44.13
Cash Conversion Cycle (CCC)	168.83	179.39	158.38
Capital & Investment Metrics	-	-	-
Invested Capital	108	104	99
Invested Capital Turnover	1.19	1.30	0.96
Increase / (Decrease) in Invested Capital	4.38	4.57	-9.82
Enterprise Value (EV)	543	438	417
Market Capitalization	553	454	426
Book Value per Share	$8.33	$8.48	$7.74
Tangible Book Value per Share	$3.55	$3.59	$2.82
Total Capital	148	149	118
Total Debt	30	29	10
Total Long-Term Debt	30	29	0.00
Net Debt	-11	-16	-9.00
Capital Expenditures (CapEx)	3.49	2.92	3.37
Debt-free, Cash-free Net Working Capital (DFCFNWC)	21	17	17
Debt-free Net Working Capital (DFNWC)	61	63	36
Net Working Capital (NWC)	61	63	26
Net Nonoperating Expense (NNE)	7.59	-1.64	12
Net Nonoperating Obligations (NNO)	-11	-16	-9.00
Total Depreciation and Amortization (D&A)	9.00	8.89	9.19
Debt-free, Cash-free Net Working Capital to Revenue	16.38%	13.11%	16.52%
Debt-free Net Working Capital to Revenue	48.19%	47.32%	35.53%
Net Working Capital to Revenue	48.19%	47.32%	25.52%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.82)	($0.11)	($1.96)
Adjusted Weighted Average Basic Shares Outstanding	14.15M	14.03M	13.92M
Adjusted Diluted Earnings per Share	($0.82)	($0.11)	($1.96)
Adjusted Weighted Average Diluted Shares Outstanding	14.15M	14.03M	13.92M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	14.33M	14.16M	14.04M
Normalized Net Operating Profit after Tax (NOPAT)	-3.95	4.50	-15
Normalized NOPAT Margin	-3.13%	3.40%	-15.48%
Pre Tax Income Margin	-5.95%	1.88%	-22.50%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-1.66	1.40	-36.78
NOPAT to Interest Expense	-1.12	-0.91	-25.87
EBIT Less CapEx to Interest Expense	-2.65	0.57	-42.41
NOPAT Less CapEx to Interest Expense	-2.10	-1.75	-31.50
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Surmodics' official financial filings.

Metric	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022	6/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-12.12%	-2.06%	-42.19%	17.50%	22.54%	7.63%	111.17%	4.18%	8.39%	8.41%	4.11%
EBITDA Growth	-167.83%	-114.20%	-113.61%	132.79%	139.62%	95.61%	587.38%	-73.89%	-404.80%	-347.07%	-769.12%
EBIT Growth	-795.06%	-567.30%	-125.39%	108.82%	95.01%	63.20%	402.51%	-35.93%	-115.79%	-1,347.60%	-184.83%
NOPAT Growth	-386.26%	-670.50%	-149.34%	121.28%	95.55%	62.95%	252.35%	-34.35%	-110.08%	-1,252.35%	-199.62%
Net Income Growth	-2,208.91%	-364.50%	-202.83%	103.19%	89.98%	145.45%	229.99%	-89.40%	-178.91%	-4,996.19%	-71.92%
EPS Growth	-1,900.00%	-333.33%	-201.92%	103.64%	89.29%	145.28%	226.83%	-89.66%	-180.00%	-5,200.00%	-70.83%
Operating Cash Flow Growth	-87.20%	10.21%	-107.85%	0.00%	18.61%	150.00%	840.38%	-38.69%	-53.74%	-381.21%	-226.93%
Free Cash Flow Firm Growth	-17.88%	-202.59%	-168.46%	257.41%	1,355.45%	-221.08%	147.71%	98.45%	116.51%	113.11%	-9,468.33%
Invested Capital Growth	-3.35%	0.00%	12.66%	-0.17%	0.00%	4.60%	-14.01%	-3.32%	-10.27%	-8.99%	64.13%
Revenue Q/Q Growth	-6.14%	0.00%	-5.06%	0.00%	9.23%	-46.71%	92.97%	9.08%	-4.06%	4.56%	-4.80%
EBITDA Q/Q Growth	-543.45%	0.00%	-319.48%	0.00%	1,163.54%	-100.81%	628.78%	13.43%	-17.73%	9.56%	-88.66%
EBIT Q/Q Growth	-66.60%	0.00%	-1,023.34%	0.00%	84.96%	-111.43%	420.68%	9.46%	-10.92%	6.06%	-44.10%
NOPAT Q/Q Growth	-61.63%	0.00%	-483.28%	0.00%	86.86%	-122.51%	265.31%	8.94%	-9.32%	7.42%	-45.78%
Net Income Q/Q Growth	-42.67%	0.00%	-3,158.30%	0.00%	-111.74%	-8.88%	195.00%	1.40%	46.75%	-160.63%	-38.40%
EPS Q/Q Growth	-38.46%	0.00%	-2,750.00%	0.00%	-112.50%	-7.69%	194.55%	1.79%	47.17%	-158.54%	-41.38%
Operating Cash Flow Q/Q Growth	112.02%	-315.80%	0.00%	0.00%	-803.36%	-95.17%	544.48%	46.07%	-332.08%	28.51%	16.74%
Free Cash Flow Firm Q/Q Growth	100.85%	0.00%	-1,476.55%	0.00%	1,852.08%	-126.79%	3,265.22%	-109.80%	45.76%	110.56%	-2.60%
Invested Capital Q/Q Growth	-2.24%	0.00%	-2.67%	0.00%	-100.00%	6.97%	-13.75%	2.13%	11.00%	-12.06%	-3.02%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	72.12%	75.19%	72.16%	77.78%	71.19%	74.83%	86.81%	78.90%	78.88%	78.46%	79.32%
EBITDA Margin	-6.64%	-0.97%	-10.58%	4.58%	6.68%	-0.69%	44.96%	-16.41%	-20.67%	-16.85%	-19.48%
Operating Margin	-14.28%	-8.29%	-17.70%	2.06%	-1.05%	-8.76%	40.80%	-24.20%	-28.99%	-25.45%	-28.74%
EBIT Margin	-14.53%	-8.18%	-17.86%	1.84%	-1.20%	-8.72%	40.68%	-24.48%	-29.50%	-25.51%	-28.40%
Profit (Net Income) Margin	-18.55%	-12.20%	-24.90%	0.77%	-2.57%	23.93%	14.00%	-28.43%	-31.46%	-56.67%	-22.74%
Tax Burden Percent	111.26%	124.01%	129.99%	148.80%	108.56%	-240.01%	35.58%	105.00%	97.94%	216.84%	78.69%
Interest Burden Percent	114.75%	120.21%	107.21%	28.28%	197.28%	114.30%	96.71%	110.62%	108.89%	102.44%	101.74%
Effective Tax Rate	0.00%	0.00%	0.00%	-48.80%	0.00%	0.00%	64.42%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-10.99%	-13.09%	0.00%	0.00%	0.00%	-8.00%	18.03%	-15.22%	-17.73%	-17.07%	-21.66%
ROIC Less NNEP Spread (ROIC-NNEP)	26.03%	677.99%	0.00%	0.00%	0.00%	-75.42%	20.02%	79.53%	34.51%	33.59%	-20.12%
Return on Net Nonoperating Assets (RNNOA)	-1.44%	-3.36%	0.00%	0.00%	0.00%	8.24%	-2.30%	-2.22%	-1.51%	-5.39%	6.36%
Return on Equity (ROE)	-12.43%	-16.45%	0.00%	0.00%	0.00%	0.24%	15.73%	-17.45%	-19.23%	-22.46%	-15.31%
Cash Return on Invested Capital (CROIC)	-4.49%	-209.82%	0.00%	0.00%	0.00%	-7.62%	15.73%	-13.46%	-4.71%	-5.42%	-60.85%
Operating Return on Assets (OROA)	-10.21%	-6.27%	0.00%	0.00%	0.00%	-6.72%	29.15%	-14.39%	-16.95%	-14.45%	-15.76%
Return on Assets (ROA)	-13.03%	-9.35%	0.00%	0.00%	0.00%	18.44%	10.03%	-16.71%	-18.07%	-32.10%	-12.62%
Return on Common Equity (ROCE)	-12.43%	-16.45%	0.00%	0.00%	0.00%	0.24%	15.73%	-17.45%	-19.23%	-22.46%	-15.31%
Return on Equity Simple (ROE_SIMPLE)	-18.02%	-12.89%	0.00%	0.00%	0.00%	0.00%	-20.42%	-35.06%	-30.12%	0.00%	-10.26%
Net Operating Profit after Tax (NOPAT)	-2.81	-1.74	-3.76	0.98	-0.23	-1.72	7.62	-4.61	-5.06	-4.63	-5.00
NOPAT Margin	-9.99%	-5.80%	-12.39%	3.07%	-0.74%	-6.13%	14.51%	-16.94%	-20.30%	-17.81%	-20.12%
Net Nonoperating Expense Percent (NNEP)	-37.01%	-691.08%	-31.78%	-109.81%	0.00%	67.42%	-1.99%	-94.75%	-52.23%	-50.66%	-1.55%
Return On Investment Capital (ROIC_SIMPLE)	-2.01%	-1.23%	-	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	27.88%	24.81%	27.84%	22.22%	28.81%	25.17%	13.19%	21.10%	21.12%	21.54%	20.68%
SG&A Expenses to Revenue	53.57%	50.71%	54.80%	40.97%	41.04%	45.79%	24.53%	47.68%	53.09%	53.01%	51.72%
R&D to Revenue	29.79%	29.88%	32.18%	32.01%	28.36%	34.67%	21.40%	47.52%	51.11%	47.17%	52.20%
Operating Expenses to Revenue	86.40%	83.48%	89.85%	75.72%	72.24%	83.59%	46.01%	103.11%	107.87%	103.91%	108.06%
Earnings before Interest and Taxes (EBIT)	-4.08	-2.45	-5.42	0.59	-0.37	-2.44	21	-6.66	-7.35	-6.63	-7.06
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1.87	-0.29	-3.21	1.46	2.04	-0.19	24	-4.46	-5.15	-4.38	-4.84
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.96	5.08	5.07	0.00	0.00	3.78	3.94	3.14	4.47	3.93	4.16
Price to Tangible Book Value (P/TBV)	9.59	11.80	11.73	0.00	0.00	8.94	10.85	10.72	13.81	10.77	10.06
Price to Revenue (P/Rev)	3.59	4.52	0.00	0.00	3.72	3.42	3.39	3.12	4.70	4.26	5.32
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	93.06	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	1.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.00	5.10	5.40	0.00	0.00	4.21	4.40	2.95	4.37	4.19	4.50
Enterprise Value to Revenue (EV/Rev)	3.58	4.52	0.00	0.00	0.00	3.30	3.27	3.22	4.73	4.17	5.19
Enterprise Value to EBITDA (EV/EBITDA)	0.00	729.42	0.00	0.00	0.00	31.74	44.51	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	89.33	602.69	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	618.48	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	494.55	0.00	0.00	0.00	41.62	63.17	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	25.85	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.27	0.26	0.25	0.24	0.00	0.25	0.26	0.29	0.28	0.09	0.08
Long-Term Debt to Equity	0.27	0.26	0.25	0.24	0.00	0.25	0.26	0.29	0.28	0.00	0.00
Financial Leverage	-0.06	-0.01	-0.10	-0.01	0.00	-0.11	-0.12	-0.03	-0.04	-0.16	-0.32
Leverage Ratio	1.48	1.47	1.59	1.54	0.00	1.51	1.53	1.49	1.45	1.42	1.33
Compound Leverage Factor	1.70	1.76	1.70	0.44	0.00	1.72	1.48	1.64	1.58	1.46	1.35
Debt to Total Capital	21.18%	20.93%	19.99%	19.21%	0.00%	19.69%	20.71%	22.22%	21.57%	8.45%	7.40%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8.45%	7.40%
Long-Term Debt to Total Capital	21.18%	20.93%	19.99%	19.21%	0.00%	19.69%	20.71%	22.22%	21.57%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	78.82%	79.07%	80.01%	80.79%	0.00%	80.31%	79.29%	77.78%	78.43%	91.55%	92.60%
Debt to EBITDA	-7.72	38.08	0.00	0.00	0.00	2.13	3.06	-1.56	-1.74	-0.78	-1.50
Net Debt to EBITDA	0.40	-0.71	0.00	0.00	0.00	-1.16	-1.59	-0.54	-0.18	0.70	1.82
Long-Term Debt to EBITDA	-7.72	38.08	0.00	0.00	0.00	2.13	3.06	-1.56	-1.74	0.00	0.00
Debt to NOPAT	-3.39	-5.42	0.00	0.00	0.00	-9.24	42.49	-1.52	-1.63	-0.65	-0.89
Net Debt to NOPAT	0.17	0.10	0.00	0.00	0.00	5.01	-22.04	-0.52	-0.17	0.58	1.08
Long-Term Debt to NOPAT	-3.39	-5.42	0.00	0.00	0.00	-9.24	42.49	-1.52	-1.63	0.00	0.00
Altman Z-Score	6.60	8.31	0.00	0.00	0.00	5.87	5.47	4.44	6.06	6.58	7.64
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.14	5.45	3.98	4.39	0.00	3.62	2.68	3.20	3.73	1.80	2.04
Quick Ratio	3.06	3.24	2.55	2.77	0.00	2.35	1.76	1.64	2.11	0.92	1.07
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.96	-113	-16	1.17	110	-6.28	23	-0.74	7.56	5.19	-49
Operating Cash Flow to CapEx	297.49%	-2,613.91%	-211.99%	0.00%	-1,221.11%	167.11%	5,508.72%	-805.67%	-1,105.63%	-437.06%	-406.16%
Free Cash Flow to Firm to Interest Expense	1.12	-128.06	-18.27	1.32	122.88	-7.02	26.54	-0.84	9.16	27.61	-339.05
Operating Cash Flow to Interest Expense	1.11	-8.95	-2.31	0.00	-9.81	1.40	29.29	-6.59	-13.08	-13.30	-24.12
Operating Cash Flow Less CapEx to Interest Expense	0.74	-9.29	-3.40	0.00	-10.62	0.56	28.76	-7.41	-14.26	-16.34	-30.06
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.70	0.77	0.00	0.00	0.00	0.77	0.72	0.59	0.57	0.57	0.56
Accounts Receivable Turnover	10.17	9.99	0.00	0.00	0.00	12.45	12.36	8.89	11.27	10.19	10.89
Inventory Turnover	2.06	2.07	0.00	0.00	0.00	1.87	1.84	1.87	2.01	2.19	2.19
Fixed Asset Turnover	4.96	5.27	0.00	0.00	0.00	4.99	4.76	3.63	3.57	3.49	3.41
Accounts Payable Turnover	9.85	12.36	0.00	0.00	0.00	8.15	10.66	7.37	10.88	8.27	10.97
Days Sales Outstanding (DSO)	35.89	36.54	0.00	0.00	0.00	29.32	29.53	41.04	32.38	35.83	33.51
Days Inventory Outstanding (DIO)	177.36	176.01	0.00	0.00	0.00	194.88	198.12	195.05	181.65	166.68	166.46
Days Payable Outstanding (DPO)	37.05	29.54	0.00	0.00	0.00	44.80	34.23	49.54	33.54	44.13	33.28
Cash Conversion Cycle (CCC)	176.20	183.01	0.00	0.00	0.00	179.39	193.42	186.55	180.50	158.38	166.69
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	109	111	109	112	0.00	104	97	113	110	99	113
Invested Capital Turnover	1.10	2.26	0.00	0.00	0.00	1.30	1.24	0.90	0.87	0.96	1.08
Increase / (Decrease) in Invested Capital	-3.77	111	12	-0.19	-110	4.57	-16	-3.87	-13	-9.82	44
Enterprise Value (EV)	435	567	591	0.00	0.00	438	427	332	482	417	509
Market Capitalization	436	567	599	0.00	514	454	443	322	479	426	521
Book Value per Share	$7.71	$7.80	$8.29	$8.76	$0.00	$8.48	$7.95	$7.26	$7.64	$7.74	$8.94
Tangible Book Value per Share	$3.18	$3.36	$3.58	$3.93	$0.00	$3.59	$2.88	$2.12	$2.47	$2.82	$3.70
Total Capital	140	141	148	153	0.00	149	142	132	137	118	135
Total Debt	30	30	30	29	0.00	29	29	29	29	10	10
Total Long-Term Debt	30	30	30	29	0.00	29	29	29	29	0.00	0.00
Net Debt	-1.52	-0.55	-8.66	-11	0.00	-16	-15	10	3.07	-9.00	-12
Capital Expenditures (CapEx)	0.32	0.30	0.96	0.00	0.72	0.75	0.47	0.72	0.98	0.57	0.86
Debt-free, Cash-free Net Working Capital (DFCFNWC)	27	29	22	24	0.00	17	9.22	23	21	17	19
Debt-free Net Working Capital (DFNWC)	58	59	60	65	0.00	63	54	42	47	36	41
Net Working Capital (NWC)	58	59	60	65	0.00	63	54	42	47	26	31
Net Nonoperating Expense (NNE)	2.40	1.91	3.80	0.73	0.56	-8.41	0.27	3.12	2.78	10	0.65
Net Nonoperating Obligations (NNO)	-1.52	-0.55	-8.66	-11	0.00	-16	-15	10	3.07	-9.00	-12
Total Depreciation and Amortization (D&A)	2.21	2.16	2.21	0.88	2.41	2.25	2.24	2.20	2.20	2.25	2.22
Debt-free, Cash-free Net Working Capital to Revenue	21.92%	22.73%	0.00%	0.00%	0.00%	13.11%	7.06%	22.27%	20.38%	16.52%	18.95%
Debt-free Net Working Capital to Revenue	47.54%	46.76%	0.00%	0.00%	0.00%	47.32%	41.20%	40.90%	46.33%	35.53%	41.51%
Net Working Capital to Revenue	47.54%	46.76%	0.00%	0.00%	0.00%	47.32%	41.20%	40.90%	46.33%	25.52%	31.29%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.36)	($0.26)	($0.53)	$0.02	$0.00	$0.48	$0.52	($0.55)	($0.56)	($1.06)	($0.41)
Adjusted Weighted Average Basic Shares Outstanding	14.28M	14.23M	14.17M	14.15M	0.00	14.03M	14.05M	14.03M	13.98M	13.92M	13.93M
Adjusted Diluted Earnings per Share	($0.36)	($0.26)	($0.53)	$0.02	$0.00	$0.48	$0.52	($0.55)	($0.56)	($1.06)	($0.41)
Adjusted Weighted Average Diluted Shares Outstanding	14.28M	14.23M	14.17M	14.18M	0.00	14.03M	14.07M	14.03M	13.98M	13.92M	13.93M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	14.30M	14.30M	14.27M	14.26M	0.00	14.16M	14.13M	14.13M	14.13M	14.04M	14.01M
Normalized Net Operating Profit after Tax (NOPAT)	-2.81	-1.74	-3.76	0.46	-0.23	-1.72	15	-3.71	-5.06	-4.63	-5.00
Normalized NOPAT Margin	-9.99%	-5.80%	-12.39%	1.44%	-0.74%	-6.13%	28.56%	-13.64%	-20.30%	-17.81%	-20.12%
Pre Tax Income Margin	-16.67%	-9.84%	-19.15%	0.52%	-2.37%	-9.97%	39.34%	-27.08%	-32.12%	-26.14%	-28.89%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-4.77	-2.78	-6.17	0.67	-0.41	-2.73	24.15	-7.53	-8.90	-35.27	-48.68
NOPAT to Interest Expense	-3.28	-1.97	-4.28	1.11	-0.25	-1.92	8.62	-5.21	-6.13	-24.62	-34.48
EBIT Less CapEx to Interest Expense	-5.15	-3.12	-7.26	0.00	-1.21	-3.56	23.62	-8.35	-10.09	-38.31	-54.61
NOPAT Less CapEx to Interest Expense	-3.66	-2.31	-5.37	0.00	-1.06	-2.75	8.09	-6.03	-7.31	-27.67	-40.42
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Surmodics' Financials

When does Surmodics's financial year end?

According to the most recent income statement we have on file, Surmodics' fiscal year ends in September. Their fiscal year 2024 ended on September 30, 2024.

How has Surmodics' net income changed over the last 3 years?

Surmodics' net income appears to be on an upward trend, with a most recent value of -$11.54 million in 2024, falling from $4.24 million in 2021. The previous period was -$1.54 million in 2023. Find out what analysts predict for Surmodics in the coming months.

What is Surmodics's operating income?

Surmodics's total operating income in 2024 was -$5.65 million, based on the following breakdown:

Total Gross Profit: $93.05 million
Total Operating Expenses: $98.70 million

How has Surmodics revenue changed over the last 3 years?

Over the last 3 years, Surmodics' total revenue changed from $105.14 million in 2021 to $126.08 million in 2024, a change of 19.9%.

How much debt does Surmodics have?

Surmodics' total liabilities were at $59.67 million at the end of 2024, a 9.4% decrease from 2023, and a 9.5% increase since 2021.

How much cash does Surmodics have?

In the past 3 years, Surmodics' cash and equivalents has ranged from $19.00 million in 2022 to $41.42 million in 2023, and is currently $36.12 million as of their latest financial filing in 2024.

How has Surmodics' book value per share changed over the last 2 years?

Over the last 2 years, Surmodics' book value per share changed from 7.74 in 2022 to 8.33 in 2024, a change of 7.7%.

Related Companies

This page (NASDAQ:SRDX) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Surmodics (SRDX) Financials

Frequently Asked Questions About Surmodics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Surmodics (SRDX) Financials

Annual Income Statements for Surmodics

Quarterly Income Statements for Surmodics

Annual Cash Flow Statements for Surmodics

Quarterly Cash Flow Statements for Surmodics

Annual Balance Sheets for Surmodics

Quarterly Balance Sheets for Surmodics

Annual Metrics And Ratios for Surmodics

Quarterly Metrics And Ratios for Surmodics

Frequently Asked Questions About Surmodics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools